Basilea Pharmaceutica (XSWX:BSLN) Long-Term Debt: CHF75.4 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
59 GF Score
Price CHF53.10
GF Value CHF57.70
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Long-Term Debt?

Basilea Pharmaceutica XSWX:BSLN -2.93% 59 Long-Term Debt is CHF75.4 Mil as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 59/100 and a GF Value™ of CHF57.70 (Fairly Valued). The stock has 4 warning signs investors should review.

Basilea Pharmaceutica's Long-Term Debt for the quarter that ended in Dec. 2025 was CHF75.4 Mil.

Basilea Pharmaceutica's quarterly Long-Term Debt declined from Dec. 2024 (CHF95.9 Mil) to Jun. 2025 (CHF82.0 Mil) and declined from Jun. 2025 (CHF82.0 Mil) to Dec. 2025 (CHF75.4 Mil).

Basilea Pharmaceutica's annual Long-Term Debt increased from Dec. 2023 (CHF95.5 Mil) to Dec. 2024 (CHF95.9 Mil) but then declined from Dec. 2024 (CHF95.9 Mil) to Dec. 2025 (CHF75.4 Mil).

Basilea Pharmaceutica  (XSWX:BSLN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Basilea Pharmaceutica Long-Term Debt Related Terms

Basilea Pharmaceutica Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Long-Term Debt Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 94.54 131.36 95.46 95.91 75.44

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.46 95.68 95.91 81.98 75.44
XSWX:BSLN
59GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of CHF75.4 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Long-Term Debt of CHF75.4 Mil as of Dec. 2025.
Is Basilea Pharmaceutica's Long-Term Debt too high?
Basilea Pharmaceutica's current Long-Term Debt is CHF75.4 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Long-Term Debt compare to VRTX and REGN?
Basilea Pharmaceutica's Long-Term Debt of CHF75.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Basilea Pharmaceutica's current Long-Term Debt is CHF75.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.70, compared to a current price of CHF53.10 — trading 8% below its estimated fair value. The current Long-Term Debt is CHF75.4 Mil. Basilea Pharmaceutica's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Long-Term Debt is CHF75.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF53.10 is trading 8% below its estimated GF Value™ of CHF57.70. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

  • Long-Term Debt: CHF75.4 Mil
  • GF Value™: CHF57.70 vs. price of CHF53.10 (8% below fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
59GF Score

Get the complete analysis for XSWX:BSLN

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF53.10
Price
CHF57.70
GF Value